ArticleRegenerative biomaterials2026
Incorporation of imidazolium chitosan derivative yields scaffolds with enhanced antioxidant, antimicrobial and immunomodulatory properties.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing biocompatible scaffolds with physicochemical properties suitable for regenerative medicine that also support cell adhesion and proliferation, while reducing local oxidative stress, exhibiting low immunogenicity and antimicrobial properties, represents a key objective in tissue engineering. Chitosan (CS), a biocompatible and biodegradable biopolymer, has attracted considerable attention in recent years as in tissue engineering. Herein, CS scaffolds were functionalized with bioactive antioxidant/antimicrobial molecules and reinforced with natural fillers to enhance these critical properties. The incorporation of a CS derivative containing 1-methylimidazole into CS-based scaffolds, and chitin nanowhiskers as reinforcement, was investigated. The resulting scaffolds exhibited an interconnected porous structure, facilitating nutrient diffusion and cell infiltration. Rheological analysis confirmed a predominantly soft and elastic behavior. Additionally, the antioxidant activity of the scaffolds was evaluated using the DPPH assay, while its antimicrobial effects were confirmed through bacterial inhibition tests. Fibroblast proliferation assays revealed an initial rapid growth phase followed by a stabilization. Immunological studies using macrophages demonstrated an initial activation of the NFκB transcription factor that did not result in the secretion of the pro-inflammatory cytokine IL-6, suggesting a transient macrophage activation. These findings highlight the potential of these CS-based scaffolds for biomedical applications by balancing structural integrity, cell compatibility and controlled immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.